{"success":true,"code":200,"message":"KeyEeventsArray Returned successfully","data":[{"uuid":"8fb56333-c1d2-401d-8baf-9895a37de336","eventId":"e2c52d17-0cb7-4ea0-945e-07406466375c","category":"AGM/EGM","summary":"Ion Exchange India Ltd has filed its Annual Report for the financial year 2025-26, along with the Notice of the 62nd Annual General Meeting (AGM) and other statutory reports. The report highlights the company's focus on sustainability, resource recovery, and water management. Key initiatives include the commissioning of a new state-of-the-art Resin manufacturing facility at Roha, emphasizing circular economy principles, non-solvent manufacturing, and Zero Liquid Discharge (ZLD). The company is also expanding its membrane manufacturing capabilities to cater to the growing demand in desalination and water reuse markets. The Executive Chairman's message underscores the increasing urgency for sustainable water management and the promising opportunities within the industry.","keyPoints":["Annual Report for FY25-26 filed, including AGM notice.","New Resin manufacturing facility at Roha operationalized.","Focus on sustainable manufacturing, ZLD, and resource recovery.","Expanding membrane manufacturing for desalination and reuse.","Integrated water and environment management solutions offered."],"title":"Ion Exchange India Ltd Annual Report FY26 Filed","stockId":"500214","attachment":"https://www.bseindia.com/xml-data/corpfiling/AttachLive/dc8810c5-6fc3-45cb-8cf8-914423fa47a1.pdf","priority":null,"createdAt":"2026-08-18T12:02:16.000Z","updatedAt":"2026-08-18T12:02:16.000Z","stock":{"stockId":"500214","name":"ION EXCHANGE (INDIA) LTD.-$","code":"IONEXCHANG","industry":"Civil Construction","bseStockId":"500214"},"bseStockId":"500214","bseStock":{"stockId":"500214","name":"ION EXCHANGE (INDIA) LTD.-$","code":"IONEXCHANG","industry":"Civil Construction"}},{"uuid":"d6d6f70f-d2c1-44d4-9fc7-4c7fd710ee55","eventId":"c89097f6-c396-4dfb-8151-7743bf915e69","category":"Shareholding","summary":"Mysore Sudhindratheertha Adarsh, part of the Promoter Group of Excelsoft Technologies Limited, has disclosed a change in shareholding. The disclosure, filed under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, details a transaction involving 30,000 shares, representing 0.02% of the total diluted share capital. This transaction resulted in a minor adjustment to the overall promoter group's stake, which now stands at approximately 59.11%. The acquisition was made through an open market transaction on August 14, 2026.","keyPoints":["Promoter Group member disclosed shareholding change.","Transaction involved 30,000 shares, 0.02% of total capital.","Total promoter group holding adjusted to 59.11%.","Acquisition occurred via open market on August 14, 2026."],"title":"Excelsoft Technologies Promoter Group Shareholding Change","stockId":"544617","attachment":"https://www.bseindia.com/xml-data/corpfiling/AttachLive/BF24FC3A_1434_4348_9DD6_CC11A8E94C89_172313.pdf","priority":null,"createdAt":"2026-08-18T12:02:14.000Z","updatedAt":"2026-08-18T12:02:14.000Z","stock":{"stockId":"544617","name":"Excelsoft Technologies Ltd","code":"EXCELSOFT","industry":"IT Enabled Services","bseStockId":"544617"},"bseStockId":"544617","bseStock":{"stockId":"544617","name":"Excelsoft Technologies Ltd","code":"EXCELSOFT","industry":"IT Enabled Services"}},{"uuid":"6d14ba68-bf03-46fb-b441-6e458d699358","eventId":"cb145ac9-dfbd-417a-8f41-e5c53bcc4025","category":"Business Update","summary":"Jeena Sikho Lifecare Ltd announced the publication of six case studies authored by its medical professionals, including the Managing Director and senior consultants. These studies, featured in the \"Academia Journal of Medicine and Prakriti - The International Multidisciplinary Research Journal\", focus on various Ayurvedic treatments for conditions such as infertility (Vandhyatva), chronic and acute kidney disease (Vrikka Roga), piles (Arsha), and hypertension during pregnancy. The publications highlight the company's dedication to Ayurvedic research and evidence-based clinical practices. All case studies and their links are available on the company's website.","keyPoints":["Company published six case studies on Ayurvedic treatments.","Publications showcase commitment to Ayurvedic research.","Studies cover infertility, kidney disease, and piles management.","Evidence-based clinical practices are demonstrated.","Details available on company website and journal."],"title":"Jeena Sikho Lifecare Publishes 6 Ayurvedic Case Studies","stockId":"544476","attachment":"https://www.bseindia.com/xml-data/corpfiling/AttachLive/1a935eee-ca23-4309-95c3-3920f8d9c263.pdf","priority":null,"createdAt":"2026-08-18T12:02:14.000Z","updatedAt":"2026-08-18T12:02:14.000Z","stock":{"stockId":"544476","name":"Jeena Sikho Lifecare Ltd","code":"JSLL","industry":"Pharmaceuticals","bseStockId":"544476"},"bseStockId":"544476","bseStock":{"stockId":"544476","name":"Jeena Sikho Lifecare Ltd","code":"JSLL","industry":"Pharmaceuticals"}},{"uuid":"3d892f7f-8d92-44e3-893c-d4f5b5422f97","eventId":"c7bba98b-af97-4063-854a-c4b394e3ad0d","category":"Corporate Action","summary":"Blue Blends (India) Limited's Board of Directors has approved the allotment of 50,00,000 fully paid-up fresh equity shares at a price of ₹10 each on a preferential basis. This action is in accordance with an approved Resolution Plan and orders from Adjudicating Authorities, including the National Company Law Tribunal and Appellate Tribunal. The allotment includes 10,000 shares to Amit Mahendrabhai Shah and 49,90,000 shares to Neolite Polymer Industries Private Limited. Concurrently, existing promoter and public shareholder equity shares are to be cancelled and extinguished without consideration, with public shareholders receiving a smaller allotment of new shares based on their existing holdings.","keyPoints":["Board approved allotment of 50 lakh equity shares on preferential basis.","Allotment is part of an approved Resolution Plan and regulatory orders.","Existing promoter and public shares to be cancelled without consideration.","Public shareholders receive new shares in ratio of 4:150.","This is a significant corporate action under insolvency proceedings."],"title":"Blue Blends Approves Allotment of 50 Lakh Equity Shares","stockId":"502761","attachment":"https://www.bseindia.com/xml-data/corpfiling/AttachLive/c6e7aa88-9bcd-4e98-a645-7382c0051c72.pdf","priority":"trending","createdAt":"2026-08-18T12:02:14.000Z","updatedAt":"2026-08-18T12:02:17.000Z","stock":{"stockId":"502761","name":"Blue Blends (India) Ltd","code":"BLUBLND-B","industry":"Other Textile Products","bseStockId":"502761"},"bseStockId":"502761","bseStock":{"stockId":"502761","name":"Blue Blends (India) Ltd","code":"BLUBLND-B","industry":"Other Textile Products"}},{"uuid":"27460a93-769e-4d67-90e6-63c05a2c9ed7","eventId":"ccb5c071-3b3f-455f-b0c5-05823aa9fdc5","category":"Acquisitions","summary":"Alivus Life Sciences Limited announced its Board of Directors has approved the acquisition of a 76% stake in IQGEN-X Pharma Private Limited for an aggregate consideration of approximately ₹9.12 crores. The acquisition aims to expand Alivus's offerings in the API and CDMO space by integrating IQGEN-X Pharma's formulation development capabilities for oral solids, sterile injectables, and ophthalmic solutions. The transaction is expected to be completed by December 6, 2026, subject to customary closing conditions. IQGEN-X Pharma reported a turnover of INR 348 Lacs for the financial year ended March 31, 2026. This acquisition is not considered a related party transaction.","keyPoints":["Alivus Life Sciences to acquire 76% stake in IQGEN-X Pharma.","Acquisition cost is approximately ₹9.12 crores.","Deal aims to enhance API and CDMO service offerings.","IQGEN-X Pharma specializes in formulation development.","Acquisition is not a related party transaction."],"title":"Alivus Life Sciences to Acquire 76% Stake in IQGEN-X Pharma for ₹9.12 Cr","stockId":"543322","attachment":"https://www.bseindia.com/xml-data/corpfiling/AttachLive/2c21fc62-af99-4bf9-9210-d4cb0f5197aa.pdf","priority":"trending","createdAt":"2026-08-18T12:01:19.000Z","updatedAt":"2026-08-18T12:01:21.000Z","stock":{"stockId":"543322","name":"Glenmark Life Sciences Ltd","code":"ALIVUS","industry":"Pharmaceuticals","bseStockId":"543322"},"bseStockId":"543322","bseStock":{"stockId":"543322","name":"Glenmark Life Sciences Ltd","code":"ALIVUS","industry":"Pharmaceuticals"}},{"uuid":"e4bdb6e7-dc35-427d-9ce0-b5d716c3c7ed","eventId":"d7a8629a-2422-4f5e-a324-635899feb90c","category":"Board Meeting","summary":"Baid Finserv Ltd has announced that its Board of Directors will convene on August 26, 2026, to consider and approve the allotment of 72,04,099 equity shares. These shares will be issued at a face value of Rs. 2 each, with a premium of Rs. 13.10 per share. The allotment is pursuant to the exercise and conversion of an equal number of convertible warrants, following the receipt of the balance subscription amount of Rs. 11.325 per warrant, representing 75% of the issue price. The meeting will also address other inter-alia matters.","keyPoints":["Board meeting scheduled for August 26, 2026.","Consideration and approval of equity share allotment.","72,04,099 equity shares to be allotted.","Allotment follows conversion of warrants.","Issue price includes face value and premium."],"title":"Baid Finserv to Allot 72 Lakh Equity Shares Post Warrant Conversion","stockId":"511724","attachment":"https://www.bseindia.com/xml-data/corpfiling/AttachLive/715c0696-8ad5-4f7f-8634-5937e1ec03af.pdf","priority":null,"createdAt":"2026-08-18T12:01:18.000Z","updatedAt":"2026-08-18T12:01:18.000Z","stock":{"stockId":"511724","name":"Baid Finserv Ltd","code":"BAIDFIN","industry":"Non Banking Financial Company (NBFC)","bseStockId":"511724"},"bseStockId":"511724","bseStock":{"stockId":"511724","name":"Baid Finserv Ltd","code":"BAIDFIN","industry":"Non Banking Financial Company (NBFC)"}},{"uuid":"431c8006-a1a1-40a4-9994-7ce1171ff568","eventId":"65243568-5856-4f2e-a55a-e1608c95b045","category":"AGM/EGM","summary":"Pharmaids Pharmaceuticals Ltd has filed its Annual Report for the Financial Year 2025-2026 and announced the 37th Annual General Meeting (AGM) scheduled for September 11, 2026. The report and AGM notice have been sent via email to registered members, with a web-link provided to others. The company is offering remote e-voting facilities through CDSL for all AGM business items. Key dates for e-voting include commencement on September 8, 2026, and end on September 10, 2026, with a cut-off date of September 4, 2026. The filing also lists the Board of Directors, key management personnel, auditors, and registrars.","keyPoints":["Annual Report for FY 2025-26 filed.","37th AGM scheduled for September 11, 2026.","Remote e-voting facility available for members.","Key dates for e-voting and cut-off date announced."],"title":"Pharmaids Pharmaceuticals Ltd Announces 37th AGM and Annual Report 2025-26","stockId":"524572","attachment":"https://www.bseindia.com/xml-data/corpfiling/AttachLive/d76da073-50c6-4670-b223-55eb1e072998.pdf","priority":null,"createdAt":"2026-08-18T12:01:14.000Z","updatedAt":"2026-08-18T12:01:14.000Z","stock":{"stockId":"524572","name":"PHARMAIDS PHARMACEUTICALS LTD.","code":"PHARMAID","industry":"Pharmaceuticals","bseStockId":"524572"},"bseStockId":"524572","bseStock":{"stockId":"524572","name":"PHARMAIDS PHARMACEUTICALS LTD.","code":"PHARMAID","industry":"Pharmaceuticals"}},{"uuid":"224a1bd6-ecf3-489b-8856-3175a22aae9c","eventId":"4591f242-f82c-4c29-b116-b95aadb5b99d","category":"AGM/EGM","summary":"M.K. Exim (India) Ltd has announced Friday, September 18, 2026, as the cut-off and record date for its 34th Annual General Meeting (AGM) and for determining dividend eligibility for the Financial Year 2025-26. The company's Register of Members and Share Transfer Books will be closed from September 19 to September 25, 2026, inclusive. The 34th AGM is scheduled for Friday, September 25, 2026, at 11:30 AM IST, to be conducted via Video Conferencing (VC) or Other Audio-Visual means (OAVM). This record date will be used to identify shareholders eligible to vote on AGM resolutions and to receive the declared dividend.","keyPoints":["Record date set for September 18, 2026, for AGM and dividend.","Share transfer books closed September 19-25, 2026.","34th AGM to be held on September 25, 2026, via VC/OAVM.","Dividend payment for FY 2025-26 to be determined by record date."],"title":"M.K. Exim Sets Sept 18, 2026 as Record Date for AGM & Dividend","stockId":"538890","attachment":"https://www.bseindia.com/xml-data/corpfiling/AttachLive/655f58af-b861-4f07-a732-fa6db556d590.pdf","priority":null,"createdAt":"2026-08-18T12:01:14.000Z","updatedAt":"2026-08-18T12:01:14.000Z","stock":{"stockId":"538890","name":"M.K. Exim (India) Ltd","code":"MKEXIM","industry":"Distributors","bseStockId":"538890"},"bseStockId":"538890","bseStock":{"stockId":"538890","name":"M.K. Exim (India) Ltd","code":"MKEXIM","industry":"Distributors"}},{"uuid":"5a603b6c-aeca-48bd-ae79-72dc199265ef","eventId":"61db3ca5-290d-4caa-a760-ecb7761fbb52","category":"Clarification","summary":"Aegis Logistics Ltd has responded to a clarification sought by BSE Limited regarding a news item published on August 18, 2026. The company stated that it regularly evaluates strategic growth opportunities in the ordinary course of business. However, as of the current date, no definitive or binding agreements, including MOUs, have been executed, nor has the Board approved any potential transaction requiring disclosure. Aegis Logistics affirmed its commitment to adhering to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and will make appropriate disclosures for material developments.","keyPoints":["Company denies any executed definitive or binding agreements.","No potential transactions have been approved by the Board.","Regular evaluation of strategic growth opportunities is ongoing.","Commitment to SEBI disclosure norms reiterated.","Appropriate disclosures will be made for material developments."],"title":"Aegis Logistics Clarifies No Definitive Agreements for Transactions","stockId":"500003","attachment":"https://www.bseindia.com/xml-data/corpfiling/AttachLive/1955654c-a275-43c4-bee6-f27ccfdd7bda.pdf","priority":null,"createdAt":"2026-08-18T12:01:02.000Z","updatedAt":"2026-08-18T12:01:02.000Z","stock":{"stockId":"500003","name":"AEGIS LOGISTICS LTD.","code":"AEGISLOG","industry":"Trading - Gas","bseStockId":"500003"},"bseStockId":"500003","bseStock":{"stockId":"500003","name":"AEGIS LOGISTICS LTD.","code":"AEGISLOG","industry":"Trading - Gas"}},{"uuid":"3a621711-4d06-4396-9ac3-46e0f8d20030","eventId":"615a5805-782c-48fb-b32e-6492f11887fb","category":"Management Change","summary":"ITCONS E-Solutions Ltd has announced the appointment of Mr. Ajay Rana (DIN: 08721213) as an Additional Director in the category of Non-Executive Independent Director. This decision was approved by the Board of Directors on August 18, 2026, based on the recommendation of the Nomination and Remuneration Committee. Mr. Rana's appointment is for a period of one year, effective from August 18, 2026, to August 17, 2027, and is subject to shareholder approval. Mr. Rana brings over 26 years of experience in higher education leadership, research, and institutional transformation, holding Ph.D. and M.Tech. degrees. He is currently the Director General of Amity University Greater Noida and Senior Vice President of Ritnand Balved Education Foundation. He is not related to any existing directors and is not debarred from holding a directorship.","keyPoints":["Ajay Rana appointed as Non-Executive Independent Director.","Appointment is for a one-year term, subject to shareholder approval.","Mr. Rana has over 26 years of experience in higher education.","He is recognized among the World's Top 2% Scientists.","No inter-se relationship with other company directors."],"title":"ITCONS E-Solutions Appoints Ajay Rana as Independent Director","stockId":"543806","attachment":"https://www.bseindia.com/xml-data/corpfiling/AttachLive/233f2884-6eed-447e-a394-eb4f9c33a3a5.pdf","priority":null,"createdAt":"2026-08-18T12:01:02.000Z","updatedAt":"2026-08-18T12:01:02.000Z","stock":{"stockId":"543806","name":"ITCONS E-Solutions Ltd","code":"ITCONS","industry":"Diversified Commercial Services","bseStockId":"543806"},"bseStockId":"543806","bseStock":{"stockId":"543806","name":"ITCONS E-Solutions Ltd","code":"ITCONS","industry":"Diversified Commercial Services"}}],"request":{"type":"GET","url":"www.stockwatch.live/keyEvents/"}}